Vectorialis is at the forefront of developing groundbreaking technologies for advanced therapies and recombinant protein production.
Our cutting-edge solutions leverage the powerful VibroFect technology, which produces high-performing and safe non-viral nanoparticles that encapsulate nucleic acids. This innovative system includes i) a patented bench-top device that ensures optimal mixing of your selected nucleic acids, and ii) the proprietary VibroFect transfection reagent.
VibroFect technology stands out for its exceptional transfection efficiency with nucleic acid-based payloads, making it suitable for a broad spectrum of both hard-to-transfect and common eukaryotic cells. With remarkably low cytotoxicity, our approach minimizes the requisite amounts of both reagent and nucleic acids, ensuring not only effectiveness but also safety in your applications.
Company Details
- Address
- Via Teodosio, 23, Milan,lombardy 20131,italy
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.vectorialis.com/
- Keywords
- Research, DNA, RNA, Gene delivery, Gene expression, Transfection, Biotechnology, Life Sciences, Recombinant proteins, Gene editing, Advanced Therapies, Vaccines, Non-viral, Translational science, Bioengineering.
- HQ
- Milan, Lombardy
Vectorialis Questions
Vectorialis's website is https://www.vectorialis.com/
Vectorialis's LinkedIn profile is https://it.linkedin.com/company/vectorialis
Vectorialis's industry is
Biotechnology Research
Vectorialis's top competitors are
Machinezero,
Nanomug,
Biovision Ventures,
Iab - Italian Angels For Biotech,
Amyc-Biomed,
Merylo' S.r.l.,
Grünenthal Group,
European Technology Platform On Nanomedicine (Etpn Association),
Clepio Biotech,
Acytronix.
Vectorialis's categories are Biotechnology Research
